Share on StockTwits

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director Robert B. Rothermel bought 5,500 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 29th. The shares were purchased at an average price of $4.03 per share, for a total transaction of $22,165.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $80,600. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Separately, analysts at CRT Capital reiterated a “positive” rating on shares of Adamis Pharmaceuticals Corp in a research note on Tuesday, June 24th. They now have a $15.00 price target on the stock.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) opened at 4.83 on Thursday. Adamis Pharmaceuticals Corp has a one year low of $2.62 and a one year high of $11.90. The stock’s 50-day moving average is $3.77 and its 200-day moving average is $5.24. The company’s market cap is $50.7 million.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), formerly Cellegy Pharmaceuticals, Incoperates through its wholly owned subsidiaries Cellegy Holdings, Inc, Adamis Corporation and Biosyn, Inc Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc (Adamis Viral) and Adamis Laboratories, Inc (Adamis Labs).

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.